Follow-up of troponin I concentration in dogs with atrioventricular block and dual-chamber pacing in a case-matched study

Wiedemann, Nicola; Hildebrandt, Nicolai; Wurtinger, Gabriel; Henrich, Estelle; Hassdenteufel, Esther; Schneider, Matthias

doi:10.1016/j.jvc.2017.01.004

Cited by 8 publications

(6 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevations in cTnI (>0.2 ng/ml) have been documented in dogs with infiltrative myocardial disease such as myocarditis [52,53] and myocardial neoplasia [51], as well as dogs with various congenital and acquired cardiac diseases [54e56] and bradyarrhythmias [57,58]. Common canineacquired heart diseases typically cause only mild to moderate elevations in cTnI, with reported values up to 1.405 ng/ml (absolute maximum) [41] or 1.57 ng/ml (95% percentile) [54] because myocyte destruction is not a major feature of these diseases.…”

Section: Discussionmentioning

confidence: 99%

Clinical presentation, cardiovascular findings, etiology, and outcome of myocarditis in dogs: 64 cases with presumptive antemortem diagnosis (26 confirmed postmortem) and 137 cases with postmortem diagnosis only (2004–2017)

Lakhdhir

Viall

Alloway

et al. 2020

Journal of Veterinary Cardiology

View full text Add to dashboard Cite

Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre-including this research content-immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical presentation, cardiovascular findings, etiology, and outcome of myocarditis in dogs: 64 cases with presumptive antemortem diagnosis (26 confirmed postmortem) and 137 cases with postmortem diagnosis only (2004–2017)

Lakhdhir

Viall

Alloway

et al. 2020

Journal of Veterinary Cardiology

View full text Add to dashboard Cite

show abstract

“…From the diagnostic point of view, one study tried to determine if serum cTnI concentration in dogs could distinguish between cardiogenic syncope and collapse due to either generalized epileptic seizures (both with and without cardiac disease) or VVS, but due to the overlap in cTnI concentrations between groups, measurement in an individual patient is not optimally discriminatory to differentiate them [101]. In other studies, it has been proven that serum cTnI concentration is high on presentation and shows significant reduction after PM implantation [40,41,69] although lead type and severity of the arrhythmia did not shown any correlation [40].…”

Section: Clinical Presentation and Diagnosis Av Conduction Disturbancesmentioning

confidence: 99%

“…In one of these case reports, a very high serum concentration of cardiac troponin I (cTnI) was documented and the authors suggested that this biomarker might help detect dogs with AVB secondary to active myocarditis [22]. Another study proved that cTnI is high at the time of presentation in dogs with permanent AVB but showed a significant reduction over time after PM implantation [40,41]. Lead type and arrhythmia severity did not show significant correlation with cTnI [40].…”

Section: Introductionmentioning

confidence: 99%

“…Another study proved that cTnI is high at the time of presentation in dogs with permanent AVB but showed a significant reduction over time after PM implantation [40,41]. Lead type and arrhythmia severity did not show significant correlation with cTnI [40]. In human medicine, endomyocardial biopsy is the gold standard for in vivo diagnosis of myocarditis and increased serum concentrations of cTnI and cardiac troponin T are considered reliable to confirm the diagnosis [42e44].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Indications for permanent pacing in dogs and cats

Santilli

Giacomazzi²,

Vázquez³

et al. 2019

Journal of Veterinary Cardiology

View full text Add to dashboard Cite

Pacemaker implantation is considered as a standard procedure for treatment of symptomatic bradycardia in both dogs and cats. Advanced second-degree and third-degree atrioventricular blocks, sick sinus syndrome, persistent atrial standstill, and vasovagal syncope are the most common rhythm disturbances that require pacing to either alleviate clinical signs or prolong survival. Most pacemakers are implanted transvenously, using endocardial leads, but rarely epicardial leads may be necessary. To decide whether a patient is a candidate for pacing, as well as which pacing modality should be used, the clinician must have a clear understanding of the etiology, the pathophysiology, and the natural history of the most common bradyarrhythmias, as well as what result can be achieved by pacing patients with different rhythm disturbances. The goal of this review was, therefore, to describe the indications for pacing by evaluating the available evidence in both human and veterinary medicine. We described the etiology of bradyarrhythmias, clinical signs and electrocardiographic abnormalities, and the choice of pacing modality, taking into account how different choices may have different physiological consequences to selected patients. It is expected that this review will assist veterinarians in recognizing arrhythmias that may require permanent pacing and the risk-benefit of each pacing modality and its impact on outcome. ª

show abstract

“…cTnI is a myocardial intracellular protein that is released by damaged and destroyed cardiomyocytes, resulting in greatly elevated concentrations in the blood [32]. Increased levels of cTnI have been reported in dogs with mitral insufficiency [27], filariasis [3], atrioventricular block [29], cardiac hemangiosarcoma [22], and administration of doxorubicin [25]. Therefore, it has been concluded that a high cTnI concentration in the blood is not only caused by infarct necrosis of the cardiomyocytes, but also by a variety of heart lesions that induce myocardial injury [11].…”

Section: Discussionmentioning

confidence: 99%

The effect of telmisartan on the ventricular systolic function in dogs with experimental supraventricular tachyarrhythmia

Kawaguchi

Hashimoto

Yasukawa

et al. 2019

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

Maintaining a good ventricular systolic function is important in the long-term therapy of dogs with supraventricular tachyarrhythmia (SVTA). The objective of this study was to evaluate the inhibitory effect of telmisartan on myocardial injury and the resulting ventricular systolic dysfunction in a canine model of SVTA. A total of 14 dogs were randomly assigned to a Telmisartan (oral telmisartan, 1.0 mg/kg daily, n=7) or a Control (no drug administration, n=7) group; the duration of rapid atrial pacing (RAP) was 3 weeks for both groups. The cardiac troponin I (cTnI) concentration in the Control group was significantly increased after 3 weeks compared to that before RAP initiation (baseline), but no significant difference was observed in the Telmisartan group. Moreover, the cTnI concentration at 3 weeks was significantly lower in the Telmisartan group than in the Control group. The left ventricular fractional shortening was significantly decreased at 3 weeks compared to that at baseline in both groups. However, fractional shortening at 3 weeks was significantly higher in the Telmisartan group than in the Control group. The cardiac output values in the Control group were significantly decreased at 3 weeks compared with those at baseline, but no significant difference was observed in the Telmisartan group. This study demonstrates that telmisartan inhibits the reduction in ventricular systolic function and prevents myocardial injury in a canine model of SVTA. Therefore, telmisartan is suggested as a novel treatment for canine SVTA.

show abstract

Follow-up of troponin I concentration in dogs with atrioventricular block and dual-chamber pacing in a case-matched study

Cited by 8 publications

References 46 publications

Clinical presentation, cardiovascular findings, etiology, and outcome of myocarditis in dogs: 64 cases with presumptive antemortem diagnosis (26 confirmed postmortem) and 137 cases with postmortem diagnosis only (2004–2017)

Clinical presentation, cardiovascular findings, etiology, and outcome of myocarditis in dogs: 64 cases with presumptive antemortem diagnosis (26 confirmed postmortem) and 137 cases with postmortem diagnosis only (2004–2017)

Indications for permanent pacing in dogs and cats

The effect of telmisartan on the ventricular systolic function in dogs with experimental supraventricular tachyarrhythmia

Contact Info

Product

Resources

About